Clinical impact of small subclones harboring NOTCH1, SF3B1 or BIRC3 mutations in chronic lymphocytic leukemia

Haematologica. 2016 Apr;101(4):e135-8. doi: 10.3324/haematol.2015.136051. Epub 2016 Jan 27.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alleles
  • Antineoplastic Agents / therapeutic use
  • B-Lymphocytes / metabolism
  • B-Lymphocytes / pathology
  • Baculoviral IAP Repeat-Containing 3 Protein
  • Clone Cells
  • Gene Expression
  • Gene Frequency
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Inhibitor of Apoptosis Proteins / genetics*
  • Inhibitor of Apoptosis Proteins / metabolism
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Mutation*
  • Phosphoproteins / genetics*
  • Phosphoproteins / metabolism
  • Prospective Studies
  • RNA Splicing Factors / genetics*
  • RNA Splicing Factors / metabolism
  • Receptor, Notch1 / genetics*
  • Receptor, Notch1 / metabolism
  • Survival Analysis
  • Ubiquitin-Protein Ligases / genetics*
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Antineoplastic Agents
  • Inhibitor of Apoptosis Proteins
  • NOTCH1 protein, human
  • Phosphoproteins
  • RNA Splicing Factors
  • Receptor, Notch1
  • SF3B1 protein, human
  • BIRC3 protein, human
  • Baculoviral IAP Repeat-Containing 3 Protein
  • Ubiquitin-Protein Ligases